First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line
First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line Valneva to begin receiving royalties for an EB66®-based human vaccine... View Article
InFlectis BioScience raises €6 million
InFlectis BioScience raises €6 million in a Series A round to perform clinical trial in humans. Nantes, France – June... View Article
OSE Pharma merge with Effimune to create OSE Immunotherapeutics
OSE Pharma and Effimune shareholders approve merger to create OSE Immunotherapeutics Paris, Nantes, May 31, 2016 – OSE Pharma SA... View Article
Effimune, launch of an hepatocellular carcinoma study
OSE Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma under a private-public collaborative program. Paris,... View Article
BIND Therapeutics Announces Collaboration with Affilogic
BIND Therapeutics Announces Collaboration with Affilogic to Provide BIND with Access to Targeting Ligands that are Key Modulators of Anti-tumor... View Article
Ipi Santé : new member
IPISANTE is developing a customized web collaborative tool, and is performing, for healthcare and wellness professionals, digital solutions which are... View Article
UBO : new member
The University of Western Brittany (UBO) is focusing its activities in the marine areas, human and social sciences, health and... View Article
Pierre Fabre : New member
Pierre Fabre is a private pharmaceutical and dermo-cosmetics group, founded in 1962, by Pierre Fabre. In 2015, its turnover exceeded... View Article
Gene therapy, a strategic sector in the Pays de Loire region
“The CESTI IHU is a great tool to maintain and strengthen our competitiveness,” said Philippe Moullier, research director at INSERM... View Article
Green light for the european BOOST4HEALTH project
On February the 25th, the European project Boost4Health successfully passed the final selection step at the North West Europe INTERREG... View Article